Skip to content
2000
Volume 8, Issue 10
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

Heat shock protein (Hsp90) inhibitors are an increasingly interesting and important class of compounds where the first in class, natural product derived inhibitors such as 17-allylaminogeldanamycin (17-AAG), are entering late stage clinical development. Recently the emergence of synthetic, small molecule inhibitors has been described and both NVPAUY922 and BIIB021 have entered clinical development. The medicinal chemistry of these and other published small molecule Hsp90 inhibitors is described in this review.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/156802608784911644
2008-07-01
2025-05-21
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/156802608784911644
Loading

  • Article Type:
    Research Article
Keyword(s): anti-cancer; Hsp90; structure-based design
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test